|Bid||3.5600 x 4000|
|Ask||3.8000 x 4000|
|Day's Range||3.6700 - 3.8400|
|52 Week Range||3.0200 - 19.3700|
|Beta (5Y Monthly)||1.27|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 23, 2022 - Feb 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.95|
Nektar Therapeutics (Nasdaq: NKTR) today announced the promotion of Jillian B. Thomsen to Senior Vice President (SVP) & Chief Financial Officer. Ms. Thomsen has served as SVP, Finance & Chief Accounting Officer of Nektar since 2008, and is a key member of our Executive Committee. Gil Labrucherie, the company's current Chief Operating Officer & Chief Financial Officer, will be departing the company to pursue another opportunity at a private biotechnology company.
An investment climate that's suddenly turned chilly may leave promising companies out in the cold.
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...